BMC Cancer

1. FANG CH, Cheng WF, Cheng YF, Lan KL, et al
   Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes.
   BMC Cancer. 2024;24:395.
   

   >> Share

   
   

   
   Clin Cancer Res

2. TAN TJ, Sammons S, Im YH, She L, et al
   Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
   Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-2513.
   

   >> Share

   
   

   
   Gynecol Oncol

3. HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
   Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
   Gynecol Oncol. 2024;186:9-16.
   

   >> Share

   
   

   
   Histopathology

4. ANGELICO G, Salvatorelli L, Tinnirello G, Santoro A, et al
   The first evidence of mismatch repair deficiency in mesonephric-like adenocarcinoma of the endometrium: clinicopathological and molecular features of a case emphasising a possible endometrioid carcinogenesis.
   Histopathology. 2024;84:1068-1070.
   

   >> Share

   
   

   
   Oncogene

5. WEI Y, Chen Z, Li Y, Song K, et al
   The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
   Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
   

   >> Share

   
   

   
   PLoS One

6. LI L, He L, Guo W, Ma J, et al
   PMFFNet: A hybrid network based on feature pyramid for ovarian tumor segmentation.
   PLoS One. 2024;19:e0299360.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share